These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 973254)

  • 21. Levodopa addiction in idiopathic Parkinson disease.
    Borek LL; Friedman JH
    Neurology; 2005 Nov; 65(9):1508. PubMed ID: 16275855
    [No Abstract]   [Full Text] [Related]  

  • 22. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R; Schneevoigt K
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract]   [Full Text] [Related]  

  • 23. L-dopa and frontal cognitive function in Parkinson's disease.
    Lange KW; Paul GM; Robbins TW; Marsden CD
    Adv Neurol; 1993; 60():475-8. PubMed ID: 8420173
    [No Abstract]   [Full Text] [Related]  

  • 24. Psychiatric aspects of L-dopa therapy of Parkinson's disease.
    Pearlman CA; Sax DS; Feldman RD
    Psychiatry Med; 1972 Jan; 3(1):45-50. PubMed ID: 4679766
    [No Abstract]   [Full Text] [Related]  

  • 25. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study.
    Meco G; Alessandri A; Giustini P; Bonifati V
    Mov Disord; 1997 Jul; 12(4):610-2. PubMed ID: 9251085
    [No Abstract]   [Full Text] [Related]  

  • 27. The treatment with L-dopa and amantadine in Parkinson's disease.
    Pendefunda G; Pollingher B; Stefanache F; Gavril A; Oprisan C; Merling M; Nemteanu E; Ciunru M; Koropitzer I
    Ther Hung; 1975; 23(1):12-6. PubMed ID: 1105871
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 30. Response to lithium in a case of L-dopa-induced psychosis.
    Braden W
    Am J Psychiatry; 1977 Jul; 134(7):808-9. PubMed ID: 869062
    [No Abstract]   [Full Text] [Related]  

  • 31. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison between EEG-finding and clinical picture in patients with Parkinsonism under L-dopa].
    Bengesser G
    Wien Med Wochenschr; 1975 Feb; 125(7-8):120-1. PubMed ID: 1146347
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical subtypes of Parkinson disease].
    Poewe W; Gerstenbrand F
    Wien Med Wochenschr; 1986 Aug; 136(15-16):384-7. PubMed ID: 3788189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y
    Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677
    [No Abstract]   [Full Text] [Related]  

  • 38. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 39. [L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
    MMW Fortschr Med; 2001 May; 143 Suppl 2():93. PubMed ID: 11434272
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination therapy of extrapyramidal disease with trihexyphenidyl and L-dopa: an electromyographic study with specific reference to tremor.
    Hökendorf H
    J Int Med Res; 1979; 7(1):19-28. PubMed ID: 421963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.